Xconomy

MAY 22, 2020

But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies. On Friday, three firms added their names to the list of life science companies preparing to join the public markets. COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too.

Company 145

Company Companies Marketing Develop 145

Xconomy

JANUARY 10, 2020

Six CEOs, including five who run public companies, co-authored the letter. A letter signed by 215 people involved in the biopharma industry, including CEOs and investors, published Wednesday promised to put the “interests of patients first.”

Pricing 52

Pricing Guide San Diego Company 52

Xconomy

APRIL 17, 2019

Turning Point Therapeutics raised more than $166 million in its IPO, pricing at the top of its range and putting nearly 2 million more shares into the public markets than it had initially planned. million shares at $18 apiece, raising $166.5 million before discounts, commissions, and offering expenses.

Pricing 57

Pricing Demand Marketing Develop 57

Xconomy

APRIL 26, 2019

Biopharmaceutical companies don’t like to talk about the failures. Biogen’s (NASDAQ: BIIB ) earnings call this week was the first since its Alzheimer’s drug aducanumab failed in a Phase 3 study and eviscerated the company’s shares. The road to every new drug approval is littered with the remains of earlier failures.

News 94

News Pricing Study Company 94

Xconomy

NOVEMBER 19, 2018

The San Diego-based biotech set a preliminary $100 million target for its IPO in documents filed with securities regulators Friday. That figure will change as the company determines how many shares it will sell and at what price. Cibus has applied for a listing on the Nasdaq exchange under the stock symbol “CBUS.”

San Diego 72

San Diego Research Startup Pricing 72

Xconomy

JULY 14, 2017

Akcea Therapeutics is joining the parade of biotechs going public, but the company had to cut its stock price and sell more shares in order to pull it off. But the biotech priced its offering of 15.6 million shares at $8 apiece, well below the $12 to $14 per share range that the company had initially set for an offering of 9.6

Pricing 57

Pricing Company Companies San Diego 57

Xconomy

JULY 29, 2020

Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to evaluate its CancerSEEK test in a registrational study. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

San Diego 87

San Diego Study Capital Invest 87

Xconomy

FEBRUARY 4, 2019

Battery-technology business Maxwell Technologies has agreed to be acquired by Silicon Valley electric car company Tesla (NASDAQ: TSLA ) in an all-stock deal valued at about $218 million, the San Diego-based company announced Monday. apiece, a 55 percent premium over its stock price as of market close Feb.

Technology 46

Technology San Diego Pricing News 46

Xconomy

APRIL 13, 2017

San Diego-based Tocagen (NASDAQ: TOCA ) priced its offering of 8.5 The company had previously planned to sell 7.25 million shares priced between $10 to $12 each. Tocagen has been developing a gene therapy treatment for a deadly type of brain cancer. million shares at $10 per share.

San Diego 66

San Diego Pricing Demand Marketing 66

Xconomy

DECEMBER 18, 2018

Seismic, an enterprise software company with ambitious growth plans, has raised $100 million in a Series E financing and added Microsoft chairman John W. The venture investment, which the San Diego startup announced Tuesday, is one of only a few so-called mega-rounds—$100 million or more—recorded this year in the region.

Southern California 110

Southern California San Diego Software Invest 110

Xconomy

DECEMBER 10, 2018

ASG Technologies, the Florida-based software company backed by activist hedge fund Elliott Management, has upped its offer for San Diego’s Mitek Systems to $11.50 26 letter the Florida-based software company made public Monday. The stock price of Mitek (NASDAQ:MITK) rose nearly 9 percent on the news, closing at $9.75.

Pricing 43

Pricing Acquisition News Software 43

Xconomy

MARCH 10, 2017

The San Diego-based biotech filed the paperwork Thursday for an IPO that could raise up to $86 million—a figure likely to change as the company determines how many shares it will sell, and at what price. Tocagen has applied to the Nasdaq Exchange for a listing under the stock symbol “TOCA.”

San Diego 79

San Diego Pricing Southern California Develop 79

Xconomy

APRIL 23, 2019

As public backlash against high drug prices shows no signs of waning, a private nonprofit in Boston, the Institute for Clinical Economic Review (ICER), has emerged as the country’s top drug-pricing watchdog. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 104

Pricing Report Funding San Diego 104

Xconomy

MARCH 12, 2018

Her out-of-pocket costs were pretty reasonable until two years ago, she says, when she had to switch insurance companies. For 20 years, Deborah Long (pictured) has been relying on powerful drugs to keep her multiple sclerosis in check. Her new insurer made her switch to a different drug, Copaxone.

Pricing 71

Pricing San Diego Company Companies 71

Xconomy

NOVEMBER 26, 2019

The company said an interim analysis showed no benefit compared to the placebo. On the same day the company said CEO George Tidmarsh had left “to pursue other interests,” and that a search for a new chief executive was underway.

Pricing 63

Pricing Study Product San Diego 63

Xconomy

JANUARY 31, 2020

million more shares than anticipated and pricing at the high end of its planned range. The stock price closed at $21.80, up 28 percent. The company joins the public markets with four product candidates in its pipeline, all topical non-steroidal treatments being developed for seven dermatological indications.

Westlake Village 114

Westlake Village Pricing Develop Development 114

Xconomy

AUGUST 15, 2019

TuSimple, an autonomous trucking company, has been conducting test drives for UPS between the Arizona cities of Phoenix and Tucson since May.

San Diego 79

San Diego Startup Technology Company 79

Xconomy

AUGUST 31, 2020

Akcea Therapeutics is returning to its parent company, Ionis Pharmaceuticals, in a $500 million deal that brings an end to a tumultuous three years as a standalone company. That price is a 60 percent premium to the Boston-based company’s closing stock price on Friday. Akcea develops drugs for rare diseases.

Pricing 89

Pricing Product Develop Development 89

Xconomy

JUNE 16, 2016

In San Diego, the complaints often focus on the relative scarcity of venture capital and hometown VC firms. So when the San Diego Venture Group recruited Mark Suster of Los Angeles-based Upfront Ventures to give the keynote talk Tuesday night for Startup Week San Diego, more than 800 people filled a downtown auditorium.

Venture Capital 49

Venture Capital San Diego Truecar Web 49

Xconomy

OCTOBER 6, 2016

San Diego’s Brain Corp. Before getting out on the open road, however, the company wants to show its self-driving system can clean up a mess in aisle 3 at Jimbo’s. The company actually has been test-driving its technology on floor scrubbers used to clean Jimbo’s, a San Diego natural foods grocer. “We

Product 106

Product Artificial Inteligence San Diego Training 106

Xconomy

MAY 16, 2018

A number of companies are developing drugs to block CGRP and stop migraine pain before it starts. But a common element is the abundance of a pain-inducing protein in the blood. During a migraine attack, nerves release this protein, called calcitonin gene-related peptide (CGRP).

Pricing 77

Pricing Develop Development San Diego 77

Xconomy

MAY 9, 2019

It will be hard to top last year’s flurry of biotech companies joining the public markets, but this week is shaping up to be the busiest for life science IPOs in recent memory. Five biotechs priced their IPOs and at least one more is coming. To date in 2019, 23 healthcare-related companies have gone public, the most of any sector.

Pricing 110

Pricing Research Capital Marketing 110

Xconomy

OCTOBER 27, 2016

Prices for agricultural commodities such as corn, soy, and wheat are at their lowest levels in years, but investment in agricultural technology has never been better. The increase in dollars flowing to agtech comes despite commodity prices that are down 65 percent from their 2013 peak, the report says. They also queried 15 VC firms.

Venture Capital 40

Venture Capital Pricing Invest Report 40

Xconomy

SEPTEMBER 17, 2020

Dyne Therapeutics, a company developing genetic medicines for rare muscular disorders, has raised $233 million in an IPO that topped the preclinical-stage biotech’s projections. Late Wednesday, Dyne priced its offering of about 12.3 million shares at $19 each. The Waltham, MA-based biotech had previously planned to sell 10.3

Pricing 114

Pricing Technology Develop Development 114

Xconomy

DECEMBER 14, 2018

Pharmaceutical industry critics lament the cost of rare disease drugs, but some of the steepest price hikes have come on widely used insulin. The patent holder, the University of Toronto, gave companies the right to manufacture insulin. to offer competitive pricing pressure. to offer competitive pricing pressure.

Patents 77

Patents Pricing Competition San Diego 77

Xconomy

JUNE 4, 2018

Bossa Nova, along with San Francisco-based Simbe Robotics, is among a group of tech companies that are using robotics and artificial intelligence. A combination of the sheer number of products a retailer like Walmart has on offer and the pace of 24/7 shopping makes it very difficult to maintain real-time inventories. “If

Artificial Inteligence 69

Artificial Inteligence Pricing Product San Diego 69

Xconomy

JULY 7, 2016

Pernix Therapeutics is slashing its headcount by more than 20 percent as the specialty pharmaceutical company tries to move toward profitability after a streak of acquisitions. Morristown, NJ-based Pernix (NASDAQ: PTX ) will cut 60 workers , mostly from its neurology sales staff, the company said today. million net loss.

Sales 40

Sales San Diego .Net Report 40

Xconomy

SEPTEMBER 7, 2016

San Diego-based Retrophin said that its drug, sparsentan, outperformed another drug sometimes used to manage a rare kidney disease, called focal segmental glomerulosclerosis (FSGS), in a Phase 2 clinical trial. Leerink expects the company to meet with the FDA later this year. This time, he increased the price from $13.50

San Diego 40

San Diego Pricing Study Journal 40

Xconomy

MAY 17, 2019

During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. But such tools only work when companies play fair. A lawsuit is now claiming that many top generic drug makers routinely conspired to avoid competition.

Pricing 79

Pricing Competition Tool Marketing 79

Xconomy

MAY 2, 2019

The food technology company’s upsized IPO has raised $241 million to finance plans to bring its plant-based “meat” to more grocery stores and restaurants across the country. Beyond Meat priced its IPO Wednesday evening at $25 per share, which was the high end of its revised range. The El Segundo, CA-based company sold approximately 9.6

El Segundo 82

El Segundo Pricing Technology Venture Capital 82

Xconomy

MARCH 1, 2019

biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government regulation. After years of boom times, the U.S. In this Report, you’ll learn: The key indicators that suggest a possible downturn is on the way.

Report 83

Report Pricing Sales San Diego 83

Xconomy

JULY 24, 2020

EQRx launched in January during the JP Morgan Healthcare Conference with an audacious pledge to create 10 new drugs in as many years and then sell them at “dramatically” lower prices than existing medicines. This week, drug licensing deals it made with two publicly traded companies spurred it to say more. But not much.

Patents 77

Patents Conference Pricing Design 77

Xconomy

JUNE 25, 2019

Even as Uber, Lyft, and other high-profile initial public offerings underperformed out of the gate, the average share price of companies that have gone public in the US this year is up by almost 33 percent. On average, those companies’ shares are up 32.6 percent compared to their offer price at IPO.

Startup 69

Startup Pricing Company Companies 69

Xconomy

OCTOBER 5, 2018

By year’s end San Diego’s Senomyx will be part of Firmenich, a privately held Swiss fragrance and flavor company. But since then its stock price has fallen significantly, dropping below $1 per share multiple times in the past two years, which nearly got the listing booted from the Nasdaq exchange.

Pricing 81

Pricing Report Sales Company 81

Xconomy

NOVEMBER 1, 2018

Under the agreement , Illumina (NASDAQ: ILMN ) will pay $8 per Pacific Biosciences (NASDAQ: PACB ) share, a 79 percent premium to the Wednesday closing stock price of the Menlo Park, CA, company. Though both Illumina and PacBio offer gene sequencing systems, the companies say the deal brings together complementary technologies.

Research 96

Research Pricing Technology San Diego 96

Xconomy

SEPTEMBER 27, 2018

The window for life science IPOs is still open, and five biotechs and one medical device company chose the last week of the third quarter to make their stock market debuts. On Thursday night, Emeryville, CA-based Gritstone priced its offering of 6.6 million shares at $15 apiece.

Pricing 94

Pricing Funding Marketing San Diego 94

Xconomy

JULY 25, 2019

On Wednesday evening, Castle priced its offering of 4 million shares at $16 apiece, which was the high end of its targeted price range. The Friendswood, TX, company had previously planned to sell approximately 3.4 Wednesday IPO activity also included two health IT companies. million shares in the range of $14 to $16 each.

Training 60

Training Pricing Activity Help 60